


Bahrain COVID-19 National Protocols

Disclaimer: These recommendations will be changed frequently based on available evidence about the best practices in caring for novel Coronavirus 2019 (COVID-19) disease.



Table of Content

Protocol	Page Number
COVID-19 Case Definitions	3 to 4
Visual Triage checklist for healthcare facilities	5 to 6
COVID-19 Risk Assessment and Stratification	7 to 9
COVID-19 Testing Protocol	10 to 17
Reporting COVID-19 Death	18 to 19
Airport Arrivals: Testing and Quarantine	20 to 21
COVID-19 Patient Allocation	22 to 23
Home isolation Protocol	24 to 26
Discharge Protocol and Repeat testing guidelines	27 to 30
Return to Work Criteria	31 to 32
Readmission guidelines for post-COVID19 cases	33 to 34
Guidance for management of Neonates born to Mothers with Suspected or Confirmed COVID-19 Infection	35 to 37
Treatment Guidelines and Pathways	38 to 55
Medication Order Sheet	56 to 60 2



COVID-19 Case Definitions





COVID-19 Case Definitions

Suspected Cases A <u>suspected case</u> is a person that fulfill any of the following

- 1. Any Symptoms of Fever, Cough, Shortness of Breath, loss of smell or taste, or Gastrointestinal symptoms
- 2. Acute respiratory illness with or without fever
- 3. Any patient with community acquired pneumonia requiring admission (especially if ICU admission OR Bilateral radiological infiltrates OR Hypoxic Respiratory failure)
- 4. Any admitted inpatient with unexplained severe acute respiratory infection (SARI)
- 5. Contact with a positive case with SARS-CoV2, with or without symptoms
- 6. History of Travel, with or without symptoms

Note :

- False Negative results can be seen early during the infection. Peak of viral shedding appears 3 to 5 days after the onset of disease.
- If the nucleic acid test is negative at the beginning, and case is suspected, to test on subsequent days.

Contact Cases

A contact is a person that belongs to either of the two defined groups

There are two types of contact cases

1 - Close Contact (High Risk Exposure), any of the following

- A person living in the same household as a COVID-19 case
- 2. Had direct physical contact with a COVID-19 case (e.g shaking hands, infectious secretions of a COVID-19 case)
- B. Had face-to-face contact with a COVID-19 case within 2 metres and > 15 minutes.
- 4. Was in a closed environment (e.g. classroom, meeting room, hospital waiting room, etc.) with a COVID-19 case for 15 minutes or more and at a distance of less than 2 metres
- 5. A healthcare worker (HCW) or other person providing direct care for a COVID-19 case, or laboratory workers handling specimens from a COVID-19 case without recommended PPE or with a possible breach of PPE;
- 5. A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated (if severity of symptoms or movement of the case indicate more extensive exposure, passengers seated in the entire section or all passengers on the aircraft may be considered close contacts).

2 - Casual Contacts (Low Risk Exposure)

Casual contact defined as any of contacts not listed in the close contacts, examples such as:

- Had casual contact with an ambulant COVID-19 case
- Had casual contact with presumptive (not confirmed) COVID-19 case
- Had stayed in an area presumed to have ongoing, community transmission




Visual Triage checklist for healthcare facilities

For early detection and isolation of suspected cases in any outpatient healthcare facility



7/1/2020




- Visual triage is to be used at Health Centres, A/E, Private Clinics and any Outpatient healthcare setting.
- Visual triaging is to be done on entry of patients, in order to early identify suspected cases and to isolate early if necessary

Risks	Score		
A. Exposure risk			
Contact with a confirmed case of COVID19 in the last 14days prior to symptoms onset OR Lived or worked in a facility known to be experiencing an outbreak of COVID-19 in the last 14days prior to onset of symptoms	3		
B. Clinical Signs and Symptoms			
Fever or recent history of fever	4		
Cough (new or wrosening)	4		
Shortness of breath (new or wrosening)	4		
Headache, sore throat or rhinorrhea	1		
Nausea, vomiting and/or diarrhea	1		
Chronic renal failure, Chronic heart disease, immunocompromisded patient	1		
Total Risk Score (A +B)			

If score of ≥4, isolate patient, ask to wear a mask, inform physician for assessment and call 444

6



COVID-19 Risk Assessment and Stratification



7/1/2020

444 phone risk assessment for symptomatic suspected COVID-19 cases




Sign and Symptoms	Routine Care (test within 72hrs)	Intermediate Care (test within 24hrs)	Urgent Care (Act Immediately)
Sore thorat and flu like symptoms	\checkmark	Patient wth the the following risk factors regardless the presence of symptoms (excluding "Urgent care*" symptoms) Risk factors include ANY of the following Diabetes Hypertension Heart disease Lung disease Malignancy Age>60 years	-
Loss of Smell or Taste	\checkmark		-
Myalgia	\checkmark		-
Fatigue	\checkmark		-
Fever*	Less than 38°C		≥38°C
Shortness of Breath*	-		\checkmark
Chest Pain*	-		\checkmark
Respiratiry Rate >30*	-		\checkmark
Change in Mental Status*	-		\checkmark
Oxygen Saturation*	Normal		≤93% on Room Air
Chest Xray changes* (applied in health facilities)	Normal The National Taskfo	rce for Combating the Coronavirus (COVID-19)	Changes suggetsive of Pneumonia

COVID-19 Clinic Risk Assessment for confirmed COVID-19 Cases



Sign and Symptoms	Mild: Home isolation (refer to home isolation protocol) or Isolation facility admission	Moderate to Severe: Transfer to Treatment facility
Sore thorat and flu like symptoms	\checkmark	-
Loss of Smell or Taste	\checkmark	-
Myalgia	\checkmark	-
Fatigue	\checkmark	-
Fever	Less than 38°C	≥38°C
Shortness of Breath	Х	\checkmark
Chest Pain	Х	\checkmark
Change in Mental Status	Х	\checkmark
Respiratiry Rate >30	Х	\checkmark
Saturation	Normal	Saturation ≤93% on Room Air
Chest Xray changes (applied in treatment facilities)	Normal The National Taskforce for Combating the Coronavirus (COVID-19)	Changes suggetsive of pneumonia 9



COVID-19 Testing Protocol

COVID-19 Molecular tests and Serology





- Two types of tests are available : Molecular tests (PCR) and Serology tests (Antibody test)
 - 1. Molecular (PCR) tests the presence of Viral nucleic acid, it indicates the presence of the virus
 - 2. <u>Serology</u> tests the presence of antibodies against the virus, and it <u>indicates previous infection or</u> <u>immune response</u>
- 1. Molecular testing (ie Viral testing by PCR)
 - Two methods are available : RT-PCR and Xpert Xpress SARS-CoV 2
- When to test using Molecular assays ?
 - 1. Symptomatic suspected cases
 - 2. Asymptomatic individuals with known or suspected exposure to confirmed cases
 - 3. Asymptomatic individuals withOUT known or suspected SARS-CoV-2 exposure , however early identification is needed in special settings (eg: regular screening of healthcare workers in COVID19 facilities and other certain workplace settings)
 - 4. Public health surveillance for SARS-CoV-2 (i.e. random testing for targeted subpopulations)

Molecular COVID-19 is not recommended for recovered COVID-19 cases unless clinically indicated and approved through National task force infectious diseases consultation





2. Serology

- National Taskforce for combating COVID -19 does not <u>currently</u> recommend using antibody testing as the sole basis for diagnosis of acute infection
 - antibody tests are not authorized by FDA for diagnostic purposes until this date
- Antibodies start developing within 1 to 3 weeks after infection
 - IgM and IgG antibodies arise nearly simultaneously and its uncommon to detect IgM alone
- Positive antibody test indicates a person has been infected with SARS-CoV-2
 - It does not necessarily mean they are currently infected (based on current available evidence)
 - False positive result can be expected in a population with low prevalence of COVID-19 (<5% of the population affected)
 - Serologic tests may NOT be used routinely at this time to determine if an individual is immune, until more evidence becomes available
 - It is currently not clear whether a positive serologic test indicates immunity against SARS-CoV-2
- Serologic assays may be used to <u>support clinical assessment</u> of a person who present late in their illness, in conjunction with viral molecular tests





COVID19 serology survillance startegy invloves two pouplations

Recovered COVID-19 Patients	NO previous COVID-19 diagnosis		
 Any patient who <u>was</u> infected with SARS-CoV2 Diagnosis made since 14 days or <u>longer</u> 	 Never tested for COVID19 or tested negative for COVID-19 		
 Enter serology request with particular Send Sample to BDFRMS lab; 	 Collect venous blood sample in designated centres Enter serology request with patient required information Send Sample to BDFRMS lab; where it will be recieved and processed Result available in BDF-RMS External Portal accesible to all healtcare facilities 		
Antibody result <u>reactive</u> → Reassure, consider for plasma donation Antibody result non reactive → Reassure , no action needed & repeat after 2 weeks from last non reactive result	 Antibody result <u>reactive</u> → Perform NP swab for PCR test, only if <u>Symptomatic</u> ✓ if PCR negative: Indicates Past exposure ; or need further clinical assessment for his current symptoms ✓ If PCR Positive: Active infection, proceed as per protocol Antibody result non reactive → Reassure 		



Molecular Testing for <u>CLOSE CONTACTS</u> of COVID-19 cases



NO Prior COVID-19 infection

- 1. Quarantine and arrange for NP swab
- 2. PCR testing of NP swab
- 3. If negative, quarantine for 10 days followed by exit swab
- 4. If positive, follow confirmed COVID19 case pathway

Recovered cases from previous COVID-19 infection who are a close contact of a positive case should have serology instead of molecular testing

- if serology is positive for antibodies, No need to quarantine
- if serology is negative; Quarantine for 10 days with exit swab

Suspected Cases

A <u>suspected case</u> is a person that fulfill **any** of the following


- 1. Any Symptoms of Fever, Cough , Shortness of Breath, loss of smell or taste, or Gastrointestinal symptoms
- 2. Acute respiratory illness with or without fever
- 3. Any patient with community acquired pneumonia requiring admission (especially if ICU admission OR Bilateral radiological infiltrates OR Hypoxic Respiratory failure)
- 4. Any admitted inpatient with unexplained severe acute respiratory infection (SARI)
- 5. Contact with a positive case with SARS-CoV2, with or without symptoms
- 6. History of Travel, with or without symptoms

Note :

- False Negative results can be seen early during the infection. Peak of viral shedding appears 3 to 5 days after the onset of disease.
- If the nucleic acid test is negative at the beginning, and case is suspected, to test on subsequent days.







Suspected Cases

A <u>suspected case</u> is a person that fulfill **any** of the following

- 1. Any Symptoms of Fever, Cough, Shortness of Breath, loss of smell or taste, or Gastrointestinal symptoms
- 2. Acute respiratory illness with or without fever
- 3. Any patient with community acquired pneumonia requiring admission (especially if ICU admission OR Bilateral radiological infiltrates OR Hypoxic Respiratory failure)
- 4. Any admitted inpatient with unexplained severe acute respiratory infection (SARI)
- 5. Contact with a positive case with SARS-CoV2, with or without symptoms
- 6. History of Travel, with or without symptoms

Note :

- False Negative results can be seen early during the infection. Peak of viral shedding appears 3 to 5 days after the onset of disease.
- If the nucleic acid test is negative at the beginning, and case is suspected, to test on subsequent days.





The following procedures apply to all HCP and lab personnel <u>exposed</u> to positive/suspected COVID19 cases

High Risk Defined as prolonged (15min) close contact without recommended PPE Exposure during the performance of an aerosolizing procedure without recommended PPE

- 1. Isolate and test for COVID-19 and wait for result
- 2. HCP working in COVID-19 facilities can undergo testing in their facility. Otherwise, can be tested in testing center
- 3. If positive, admit in isolation facility/Home isolation
- 4. If negative*, home isolation 10 days
- 5. Retest at the end of the isolation period before going back to work

*If the PCR test is negative, and case is suspected, to test on subsequent days.

Low Risk Defined as exposure other than high risk, without recommended PPE

- 1. Isolate and test for COVID-19 and wait for result
- 2. HCP working in COVID-19 facilities can undergo testing in their facility. Otherwise can be tested in testing center
- 3. If positive, admit in isolation facility/Home isolation
- 4. If negative* and asymptomatic, can return to work with extra safety precautions (face mask and daily symptoms assessment for 10 days).
- 5. If negative* and symptomatic, home isolate until symptoms resolve for 72hrs and retest, if negative can return to work


*If the PCR test is negative, and case is suspected, to test on subsequent days.

- IN CASE OF THE INABILITY TO PROVIDE SAFE PATIENT CARE DUE STAFF SHORTAGE, any HCW with history of exposure and is asymptomatic can managed as the low risk pathway. Daily checking and recording of symptoms is mandatory for those individuals. In case of any symptoms appear, immediately isolate and retest. If negative, HCW can return to work when asymptomatic for atleast 72 hrs
- All HCW should report any symptoms or unprotected exposure to confirmed cases of COVID19, to their designated department and 444


All healthcare providers caring for COVID19 positive cases should undergo molecular test for COVID-19 by NP swab every 7 days in their facilities. Results are to be traced by the facility supervisor, and to follow-up on the results accordingly

General Recommendations

- Encourage good hygiene by education and posters
- Increase the frequency of cleaning lavatories
- Distribution of hand sanitizers and tissues in the building
- Strict procedure to prevent animals entering the prison site
- Daily report about prison situation to war room



COVID-19



Reporting of COVID-19 death








Due to the current pandemic and the prevalence of the virus in the community, it is challenging to differentiate between cases who died <u>WITH</u> the virus or those who died because <u>OF</u> the virus

• There is no consensus in the literature nor a recommendation on reporting sudden death in COVID-19

The National task force provides the following recommendations for reporting cases of sudden death outside the COVID-19 pathway (ie at home)

- 1. If swab is taken before death and turns to be positive:
 - Patient will be counted as a case of COVID19; however mortality will not be reported due to COVID19, if no clinical evidence is present
- 2. If swab is taken after death of the individual and is positive
 - The case will NOT be counted neither as a case of COVID19 nor as a case of COVID-19 Death





Airline Arrivals: Testing and Quarantine protocol


Phase 1






Airline Arrivals: Testing and Quarantine







COVID-19 Patient Allocation





Patient Allocations




COVID-19 patients will be allocated to the following categories based on the presented symptoms and criteria:

- <u>Home isolation</u>: Subject to specific criteria (refer to Home isolation protocol)
- Isolation facilities: Asymptomatic or Mildly symptomatic cases who don't fit home isolation
 - Mild symptoms: Shamil Field Hospital (SFH), KBH (Private)
 - Asymptomatic: Shamil Field Hospital (SFH), Hidd Isolation, Sitra Camp, Other NHRA approved private facilities
- <u>Treatment Facilities</u>: Mild to Moderate Disease and those who require in-hospital medical care and to follow <u>admission office criteria</u>
 - •EKK: Mild-Moderate pneumonia, or Mild cases with comorbidities that need hospital management i.e. Hemodialysis
 - •JMH: Mild-Moderate pneumonia, Mild cases with comorbidities that need hospital management, Paediatric, and uncomplicated Obstetric cases
 - •BIH: Mild pneumonia, or Mild cases with comorbidities that need hospital management
 - •SMC 6th floor: cases requiring other subspecialty care
 - •RAF: Non Bahraini with Mild pneumonia, or any Mild cases with comorbidities that need hospital management or cases requiring nursing care

•HBDC (H2+3+4): Moderate Pneumonia (as per admission office eligibility)

- ICU Facilities : Severe Diseases or cases who require advanced therapies
 - •HBDC (H1), BDF FICU, Sitra FICU
- MKCC Facility: VIP Cases subject to prior approval



Home isolation Protocol








Criteria that must be met to qualify patients for Home Isolation:

- 1. Age less than 60 years old
- 2. Asymptomatic or mildly symptomatic
- 3. Absence of risk factors
 - Risk factors defined as : Chronic diseases or Age 60 or above
- 4. Appropriate home setting for a self isolation
- 5. No household members with an immunocompromised state
- 6. Able to stay in contact with the medical team electronically
- 7. Activation of "Be Aware Bahrain" App

7/1/2020 Household contacts should be managed as close contacts 25

Home Isolation Protocol






Discharge from home isolation

- After completion of 10days in home isolation while being asymptomatic at least 72hrs prior to discharge; patient can be discharged without a PCR test
- 10 days of home isolation is counted from onset of symptoms if patient is symptomatic ; otherwise will be counted from diagnosis
- Patients can return electronic bracelet to his/her health center **with** deceleration form






Discharge Protocol and Repeat testing guidelines

for Quarantine and Isolation/Treatment facilities



Testing and Discharge Protocol for Patients in Institutional or Home Quarantine (Close contacts with NEGATIVE PCR)





7/1/2020





The Following Procedures Govern Discharge of Patients who are Mildly symptomatic or Asymptomatic at Treatment Facilities


Mild Symptoms

- Absence of Pneumonia
- Symptoms limited to upper respiratory tract

Discharge criteria

- Resolution of symptoms for atleast 72hrs prior to discharge
- (2) <u>One</u> negative NP Swab Isolation instruction
- Need to complete a total of 10 days of self isolation since onset of symptoms (or since date of their first positive COVID-19 test if Asymptomatic)
- Follow home isolation instruction with the use of BeAware App
- Sick leave to be issued from the discharging treatment facility

Return to work Refer to the Return to work protocol/1/2020




If patient has persistent positive PCR + completed 10 days as inpatient + atleast 72hrs have passed since resolution of symptoms – Discharge Patient with <u>additional</u> 1 week of home isolation

Patient that has passed >8 days from onset of symptoms and SARS-CoV2 E gene RT-PCR CT Value >24 may predict lack of infectivity (reference)








Return to work Refer to the Return to work protocol 7/1/2020 resolution of symptoms – Discharge Patient with additional 1 week of home isolation

Patient that has passed >8 days from onset of symptoms and SARS-CoV2 E gene RT-PCR CT Value >24 may predict lack of infectivity (reference)



Return to Work Criteria








- Recovered COVID-19 patients (Non-Health Care Workers) can return to work whenever:
 - 1. They are Asymptomatic for atleast 72 hours
 - 2. AND have completed the isolation period specified by the discharge protocol.
- <u>Healthcare workers</u> can return to work based on <u>one</u> of the following criteria:
 - 1. 72 hours have passed from resolutions of symptoms <u>AND</u> has 2 consecutive negative NP swabs that are at least 24hr apart
 - Patient is asymptomatic for atleast 72hours <u>AND</u> 10 days have passed from diagnosis <u>AND</u> 1 negative NP swab.
 - All recovered HCW should have serology testing after 2 weeks from diagnosis
 - Weekly PCR is NOT required unless requested by infectious Diseases consultant





Recovered COVID-19 Cases : Readmission guidelines





Readmission guideline

<u>Definition of Recovered Case</u>: Recovered COVID-19 cases are patients who were diagnosed with COVID19 and fulfilled all the isolation and discharge criteria

<u>Definition of COVID-19 Pathway</u> refers to all the processes encountered in a confirmed COVID-19 case from the diagnosis until satisfying discharge criteria and end of isolation

Within 14 days from COVID-19 Pathway Discharge

- 1. Any Recovered COVID-19 who presented with COVID-19 related symptoms, can be readmitted to COVID-19 facilities if clinically indicated.
 - If Recovered cases develops respiratory symptoms, consider investigating for post COVID-19 complications (such as bacterial pneumonia, VTE) and other infections.
- 2. If Recovered COVID-19 patients presents with non COVID related illness and requires admission to a non covid facility relating to his presenting illness, patient can be admitted to the appropriate medical are facility with infection control precaution

After 14 days from COVID-19 Pathway Discharge :


Patient follow normal care pathway, unless indicated otherwise

Scientific Justification

Reference: Alberta Health Services Scientific Advisory Group COVID-19 Recommendations

- The possibility of reinfection with SARS-CoV-2 is very unlikely : there have been no well substantiated cases of reinfection to date and most of the suspect cases are likely related to inconsistent detection of prolonged viral RNA shedding.
- Current evidence suggest that viable virus declines relatively quickly in initial infection, but RT- PCR positivity can be prolonged
- Rising antibody titers over the second and third week of illness are likely protective or partially protective. However, The duration of likely immunity is unclear as yet, but reinfection is unlikely in the short term.





Guidance for management of Neonates born to Mothers with Suspected or Confirmed COVID-19 Infection







Newborns should be separated at birth from their mother and bathed as soon as possible Neonate to be kept in isolation from other infants NP swab for mother – use Gene Xpert for more rapid results

Mother tetsed Positive

If mother tetsed Negative and neonate is asymptomatic and stable, discharge from COVID pathway

Tests newborn for COVID-19 at 24hours of age (oro+nasopharyngeal in one swab) and if negative, repeat at 48hours of age

• If testing is limited and baby is stable and asymptomatic and are expected to be discharged before 48 hours a single test can be done at 24-48 hours

If both PCR tests negative and neonate is asymptmatic and stable, can be discharged and to follow the advised guidelines (page 37)

If newborn tested positive, follow COVID-19 Pathway

- 1. Newborns can remain with their mothers
- 2. Observe for the development of any symptoms
- 3. Discharge once two consecutive negative NP test
- 4. Plan for frequent follow-up through 14 days after birth

If neonate is symptomatic or unstable, follow institutional protocol and provide appropriate care in an isolation room and perform COVID19 swabs as indicated if mother tested positive or mother under investigation.

Source: American Academy of Pediatrics and KSA guidelines





The following guideline are recommended regarding Neonate born to Mothers with Confirmed COVID-19 Infection

- Temporary separation between the mother and the newborn minimizes the risk of transmission and is advised
 - If parents refuse separation and willing to room in together, then precautions should be taken to minimize risk of viral transmission:
 - 1. Staying 2 meters away from the mother,
 - 2. practice safe hand hygiene
 - 3. wear a mask
- Breastfeeding: mothers may express breast milk after appropriate breast and hand hygiene. Caregivers who are not infected may feed the breast milk to the infant
 - Mother who request direct breastfeeding, should understand the increased risk of transmission and comply with strict preventive precautions that include use of a mask and meticulous breast and hand hygiene.

Source: American Academy of Pediatrics





Treatment Guidelines and Pathways





Treatment Guidelines : General approach



- Daily clinical assessment of patients is required
- It have been reported that deterioration is more common within the 8 to 10 days from symptoms onset
- Strict Isolation and adherence to infection control measures
- Baseline investigations for all patients:
 - ECG, Chest Xray/ Ultrasound chest
 - Echocardiography
 - CBC, Urea/Electrolytes, Creatinine, LFT
 - CRP, LDH, ESR, D-Dimer, Ferritin, PCT
- Risk stratification and prognostic markers
 - D-dimer, Fibrinogen, PT/PTT, Mg
 - Ferritin, CRP, ESR, PCT
 - LDH, Troponin, BNP
 - VWF, IL6
- All Patients should have the baseline investigations done, with the addition of Blood Grouping and Vitamin D level
- Avoid Hydroxychloroquine with Azithromycin due to increased risk of cardiac arrythmias
- Disclaimer
 - At present, no drug has been proven to be safe and effective for treating COVID-19. There are insufficient data to recommend either for or against the use of any antiviral or immunomodulatory therapy in patients with COVID-19 who have mild, moderate, severe, or critical illness
 - Guidelines are created based on best available evidence. Physicians should use this as a guide and depend on clinical and scientific judgment and individualizing of care
 - Physician should use this as a guide and depend on clinical and scientific judgment and individualizing of care
 - This guideline is subject to change based on more evidence and will be updated regularly whenever needed





Definition:

- non-specific symptoms such as fever, cough, sore throat, nasal congestion, malaise, headache, muscle pain.
- These patients do not have any signs of dehydration, sepsis or shortness of breath.

Suppor

 \circ

0

Absence of signs of pneumonia

*Risk Factors: any ONE of :

- Age ≥65 years
- Residence in a nursing home or long-term care facility
- Immunocompromising
 condition
- Chronic lung disease or moderate to severe asthma
- Cardiovascular disease (including hypertension)
- Severe obesity (body mass index [BMI] ≥40 kg/m₂)
- Diabetes mellitus
- Chronic kidney disease (undergoing dialysis)
- Cerebrovascular disease
- Chronic liver disease
- Tobacco use disorder

Immediately implement strict infection control measures			
	1		
e <mark>rtive care:</mark> IVF Antipyretics (Avoid NSAID) Symptomatic care			

Consider the use of Zinc, Vitamin C and Vitamin D

Consider the use of Hydroxychloroquine if fitting the criteria (page 50)

Consider **Thromboprophylaxis with low molecular weight heparin (LMWH)** if not contraindicated (page 43)

Regular laboratory investigations for individuals with risk factors*

Bas	seline investigations :	Risk stratification and prognostic markers (Daily fo
• E	CG, Chest Xray/ Ultrasound chest	individuals with risk factors)
• C	BC, Urea/Electrolytes, Creatinine, LFT	D-dimer, Fibrinogen, PT/PTT, Mg
• B	lood Group and Vitamin D	Ferritin, CRP, ESR, PCT
• C	RP, LDH, ESR, D-Dimer, Ferritin, PCT (and Respiratory panel PCR if	• LDH, Troponin, BNP
a	vailable)	• VWF, IL6

Guidelines are created based on best available evidence.

Physicians should use this as a guide and depend on clinical and scientific judgment and individualizing of care 40

Pneumonia



Definition Immediately implement strict infection control measures **Pneumonia:** Patient with pneumonia and no signs of severe pneumonia. Severe Pneumonia Pneumonia Child with non-severe pneumonia has cough or difficulty breathing + tachypnea ICU Consultation and ICU care Severe Pneumonia: ICU Consultation and ICU care if necessary • Supportive care: Adolescent or adult: • Supportive care: o IVF, Antipyretics (Avoid NSAIDS) and Symptomatic care fever or suspected respiratory infection, IVF 0 Oxygen (keep saturation >94%, start with 5L) plus one of Antipyretics (Avoid NSAIDS) and Symptomatic care 0 o Ventilatory support if needed respiratory rate >30 breaths/min Oxygen (keep saturation >94%, start with 5L) 0 severe respiratory distress • Consider the use of Remdesivir or Favipiravir SpO2 <93% on room air • Consider the use of Zinc, Vitamin C and Vitamin D Convalescent Plasma Therapy Lung infiltrates >50% of the lung field • Consider the use of Remdesivir or Favipiravir • Dexamethasone or Methylprednisolone (if evidence of hypoxia) within 24-48 hours Convalescent Plasma Therapy Ferritin >500 ug/L; Ddimer >1mg/L ; • Consider the use of Plasmapheresis in a selected group of CRP>100mg/L; LDH>245 U/L; Elevated • Dexamethasone or Methylprednisolone (if evidence of hypoxia) patients, on case to case basis, as per facility protocol Troponin • LMWH/UFH if not contraindicated (refer to pg 43) • Consider the use of Tocilizumab if fitting criteria • Rule out other causes of pneumonia and PE • LMWH/UFH if not contraindicated (refer to pg 43) Child with cough or difficulty in breathing, plus at least one of the • Rule out other causes for pneumonia and PE following: Central cyanosis SpO2 <93%; severe respiratory distress (e.g. Investigations grunting, very severe chest indrawing); **Baseline investigations :** Risk stratification and prognostic markers (q12hr) signs of pneumonia with a general • ECG, Chest Xray/Ultrasound chest • D-dimer, Fbrinogen, PT/PTT, Mg danger sign: • CBC, Urea/Electrolytes, Creatinine, LFT Ferritin, CRP, ESR, PCT inability to breastfeed or drink, • CRP, LDH, ESR, D-Dimer, Ferritin, PCT • LDH, Troponin, BNP lethargy or unconsciousness, or Blood group and Vitamin D • VWF, IL6 convulsions. and Respiratory panel PCR (if available) Daily: CBC, Biochemistry, ECG

Guidelines are created based on best available evidence. 41 Physicians should use this as a guide and depend on clinical and scientific judgment and individualizing of care

• Other signs of pneumonia may be present: chest indrawing and tachypnea.

<u>Definition</u>

Onset: new or worsening respiratory symptoms within one week of known clinical insult.

Chest imaging (radiograph, CT scan, or lung ultrasound): bilateral opacities, not fully explained by effusions, lobar or lung collapse, or nodules.

Origin of edema: respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic cause of edema if no risk factor present.

Oxygenation (adults):

- Mild ARDS: 200 mmHg < PaO2/FiO2 ≤ 300 mmHg (with PEEP or CPAP ≥5 cmH2O,
- Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤200 mmHg with PEEP ≥5 cmH2O
- Severe ARDS: PaO2/FiO2 ≤ 100 mmHg with PEEP ≥5 cmH2O,
- When PaO2 is not available, SpO2/FiO2 ≤315 suggests ARDS (including in non-ventilated patients)

Oxygenation (children):

- Bilevel NIV or CPAP ≥5 cmH2O via full face mask: PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤264
- Mild ARDS (invasively ventilated): 4 ≤ OI < 8 or 5 ≤ OSI < 7.5
- Moderate ARDS (invasively ventilated): 8 ≤ OI
 < 16 or 7.5 ≤ OSI < 12.3
- Severe ARDS (invasively ventilated): OI ≥ 16 or OSI ≥ 12.3

OI= Oxygenation Index and OSI = Oxygenation Index using SpO2

Immediately implement strict infection control measures

- ICU Consultation and ICU care
- <u>Supportive care:</u>
 - o IVF, Antipyretics (Avoid NSAIDS) and Symptomatic care
- o Oxygen (keep saturation >94%, start with 5L)
- o Ventilatory support if needed
- Consider the use of Remdesivir or Favipiravir
- Convalescent Plasma Therapy
- Dexamethasone or Methylprednisolone (if evidence of hypoxia)
 - Consider the use of Plasmapheresis in a selected group of patients, on case to case basis, as per facility protocol
- Consider the use of Tocilizumab if fitting criteria
- LMWH/UFH if not contraindicated (refer to pg 43)
- Rule out other causes for pneumonia and treat accordingly
- Rule out the possibility of PE incase of worsening hypoxia

Baseline investigations :

- ECG, Chest Xray/ Ultrasound chest
- CBC, Urea/Electrolytes, Creatinine, LFT
- CRP, LDH, ESR, D-Dimer, Ferritin, PCT
- Blood Group and Vitamin D
- and Respiratory panel PCR (if available)

Investigations

Risk stratification and prognostic markers (q12hr)

لحملة الوطنية

لمـكافحة فـيروس كورونـ (COVID-19)

- D-dimer, Fbrinogen, PT/PTT, Mg
- Ferritin, CRP, ESR, PCT
- LDH, Troponin, BNP
- VWF, IL6
- Daily: CBC, Biochemistry, ECG
- Consider ruling out PE (by echo or CTPA)

Guidelines are created based on best available evidence.

Physicians should use this as a guide and depend on clinical and scientific judgment and individualizing of care

Thromboprophylaxis dosing schedule



D-Dimer level (mcg/ml)	Weight (kg)	LMWH dose
	<100kg	Enoxaparin 40mg SC once daily
<1	100 – 150kg	Enoxaparin 40mg SC twice daily
	>150kg	Enoxaparin 60mg SC twice daily
	<100kg	Enoxaparin 40mg SC twice daily
>1	100 – 150kg	Enoxaparin 80mg SC twice daily
	>150kg	Enoxaparin 120mg SC twice daily

To be guided as per local facility guidelines





- For adults with COVID-19 and acute hypoxemic respiratory failure despite conventional oxygen therapy, high-flow nasal cannula (HFNC) oxygen is recommended over noninvasive positive pressure ventilation (NIPPV)
- Consider awake prone positioning to improve ventilation, if possible
- Incentive Spirometry if patient can perform
- indirect evidence from other critical illnesses suggests the optimal oxygen target is an SpO2 between 92% and 96%
- close monitoring for worsening respiratory status and intubation if necessary, in a controlled setting and by an experienced practitioner





- For mechanically ventilated adults with COVID-19 and ARDS:
 - Use low tidal volume (Vt) ventilation (Vt 4–8 mL/kg of predicted body weight)
 - Target plateau pressures of <30 cm H2O
 - Use conservative fluid strategy over a liberal fluid strategy
- For mechanically ventilated adults with COVID-19 and moderate-to-severe ARDS:
 - Use a higher positive end-expiratory pressure (PEEP) strategy over a lower PEEP strategy
- For mechanically ventilated adults with COVID-19 and refractory hypoxemia despite optimizing ventilation, use prone ventilation for 12 to 16 hours per day





Hospitalized Patients	Patients for Home isolation				
Laboratory Testing					
Measure coagulation markers (e.g., CBC, D-dimers, prothrombin There are currently no data to support the measurement of coagulatio					
time, platelet count, fibrinogen) in Hospitalized patients.	markers in non-hospitalized COVID-19 confirmed cases.				
Venous Thromboembo	lism Prophylaxis and Screening:				
Hospitalized patient should be screened and VTE prophylaxis be Anticoagulants and antiplatelet therapy should not be initiated for					
initiated.	prevention of venous thromboembolism (VTE) or arterial thrombosis				
Reference doses in page 43	unless there are other indications				
Chronic Anticoagula	nt and Antiplatelet Therapy:				
Anticoagulant or antiplatelet therapies for underlying conditions Patients who are receiving anticoagulant or antiplatelet therapies for					
should be continued unless there is need for switching to heparin	underlying conditions should continue these medications if they receive a diagnosis of COVID-19				
Special Consider	ations During Pregnancy				
Management of anticoagulation therapy in pregnant patients with	If antithrombotic therapy is prescribed during pregnancy for another				
COVID-19 is same as other conditions that require	indication, this therapy should be continued if the patient receives a				
anticoagulation in pregnancy .	diagnosis of COVID-19 and is not admitted in hospital.				
The D-dimer level may not be a reliable predictor of VTE in pregnancy, because there is a physiologic increase of D-dimer levels throughout gestation.					
Venous Thromboembolism P	rophylaxis in children with COVID-19				

venous infomboembolism Prophylaxis in children with COVID-15

Pediatric patients admitted for COVID-19 who are moderately or severely ill be given VTE risk prophylaxis in accordance with existing institutional guidelines. The National Taskforce for Combating the Coronavirus (COVID-19) 46



Routine post-discharge VTE prophylaxis is NOT recommended for patients with COVID-19.

However, the benefits of post-discharge prophylaxis for certain high-risk patients without COVID-19 led to the Food and Drug Administration approval of two regimens:

- Enoxaparin 40mg SC OD for 6 to 14 days
- Rivaroxaban 10 mg daily for 31 to 39 days

Inclusion criteria :

- Modified IMPROVE-VTE score \geq 4; or
- Modified IMPROVE-VTE score ≥2 and D-dimer level >2 times the upper limit of normal; or
- Age ≥75 years; or
- Age >60 years and D-dimer level >2 times the upper limit of normal; or
- Age 40 to 60 years, D-dimer level >2 times the upper limit of normal, and previous VTE event or cancer.17
- Any decision to use post-discharge VTE prophylaxis should consider the individual patient's risk factors, including reduced mobility, bleeding risks, and feasibility

Modified IMPROVE-VTE score

- 3 point for previous VTE
- 2 points for Thrombophilia
- 2 points for current lower limb paralysis or paresis
- 2 point for History of Cancer
- 1 point for ICU/CCU stay
- 1 point for One or more day of immobilization
- 1 point for Age more than or equal to 60 years

COVID19 Medications and Dosage



Drugs	Dose
Zinc	50mg Oral Once daily
Vitamin C	1g Oral once daily
Vitamin D (dependig of patients Vitamin D levels)	 2000units daily or 50,000units weekly Can also consider dosing related to Vitamin D Level Serum 25(OH)D 20 to 30 ng/mL: 1000 to 2000 units once daily Serum 25(OH)D 10 to <20 ng/mL: 2000U once daily or 50,000 units once weekly or 5,000 to 7,000 units once daily Serum 25(OH)D <10 ng/mL or in patients with deficiency symptoms: 50,000 units once weekly or 5,000 to 7,000 units once daily daily
Hydroxychloroquine	<u>Adult dose:</u> Day 1: loading dose of 400 mg orally every 12 hours, Day 2 to 5 : 200 mg orally every 12 hours Refer to Hydroxychloroquine protocol
Favipiravir	<u>Adult dose:</u> Day 1: 1600 mg PO twice daily (loading doses) Days 2 to 10: 600 mg PO twice daily (14 days can be considered) Refer to Favipiravir protocol
Remdisivir	Adult dose: • Day 1: 200mg IV Once Daily • Days 2 to 5: 100mg IV Once Daily may extend for up to 5 additional days in patients who do not demonstrate clinical improvement.
Dexamethasone	6mg IV OD for 5-10 days
Tocilizumab (refer to next page)	The initial dose is 4-8mg/kg (recommended dose of 400mg diluted with 0.9% normal saline to 100ml). If the initial medication is not effective, one extra administration can be given after 12 hours (same dose as before). No more than two administrations should be given, with the maximum single dose no more than 800mg. The infusion time should be more than 1 hour. Contraindicated for people with active infections such as tuberculosis. Avoid using with interferon





Risk Score Calculation to predict QT prolongation greater than 500msec			Interpretation and Recommendations		
Variable		Points	Risk Score	Risk for QT prolongation	Recommendation
Age ≥68 years		1	≤6	Low	Always consider that higher risk may develop depending on clinical course and drug interactions and pharmacokinetics.
Female		1			
Loop diuretic		1		Moderate	 Clinical Pharmacist Consultation Adjust risk factors as much as possible. EKG should be repeated after 5 half-lives of QT-prolonging drugs given to evaluate QTc.
Potassium ≤3.5 mEq/L potassium determined closest to EKG timing		2	7-10		
Admission QTc ≥450 msec		2			
Being admitted for acute myocardial infarction		2	≥11	High	 Clinical Pharmacist Consultation Adjust risk factors Use alternative medications
Being admitted for sepsis		3			
Being admitted for heart failure		3			
	None	0	211	i ligit	 EKG should be repeated after 5 half-lives of QT-prolonging drugs given to evaluate QTc.
Number of QTc-prolonging drugs given If receiving ≥2 drugs, patient receives 3 points for 1 QTc-	1 QTc-prolonging drug	3			
prolonging drug as well as 3 additional points for ≥2.	≥2 QTc-prolonging drugs	6			



Hydroxychloroquine Treatment Protocol



Category	Details		
Dose	<u>Adult dose:</u> Day 1 : Loading dose of 400 mg orally every 12 hours, 		
	 Followed by 200 mg orally every 12 hours for a total of 5 to 10 days 		
Indications (ALL apply)	Adults with mild disease (Upper respiratory tract infection) or Asymptomtatic adults with risk factors		
	 Early during the course of the disease ; less than 7 days before onset of symptoms 		
	Inpatients only		
	 Follow daily monitoring protocol, with cardiac telemetry 		
Contraindications	G6PD Deficency		
	 QTc > 500msec , or 550msec with pacing 		
	Bundle Branch Block		
	• Epilepsy		
	Porphyria		
	Pre-existing Retinopathy		
Monitoring	• QT Interval : ECG 2-3 hours after the second dose of hydroxychloroquine, and daily thereafter.		
	Serum Creatinine,		
	Potassium		
	• Magnesium		
	Liver Function tests: ALT, AST		
	Hemoglobin level		
	Plateletes		
	Blood sugar		
Adverse Effects	QT Prolongation		
	Cardiac arhythmias		
	Hypoglycemia		
L			







Category	Details
Dose	 <u>Adult dose:</u> Day 1: 1600 mg PO twice daily (loading doses) Days 2 to 10: 600 mg PO twice daily (14 days can be considered) <u>Hepatic adjustment in Child Pugh C</u> Day 1: 800 mg PO twice daily Days 2 to 10: 400 mg PO twice daily
Monitoring	 Serum Creatinine, Uric acid Liver Function tests: ALT, AST, ALP, Bilirubin WBC and Neutrophil count
Adverse effects	 Hyperuricemia Neutropenia Hepatic Injury
Drug Interaction	 Tamoxifen, Calcium Channel Blockers Loop diuretics Tricyclic antidepressants Diabetic medications Paracetmol to be limited to 3g per day
Precautions	 Caution in using in patients with pre-existing gout and gouty arthritis. Monitor for QT- prolongation if combined with other QT-prolonging agents. Testes toxicity was also noted when taking favipiravir. Contraindicated in pregnancy.



Remdesivir Treatment Protocol



Category	Details
Dose	Adult dose:• Day 1:200mg IV Once Daily• Days 2 to 5:100mg IV Once Dailymay extend for up to 5 additional days in patients who do not demonstrate clinical improvement.Indicated for patient with COVID19 requiring supplemental oxygen therapy
Contraindications	 Hypersensitivity to Remdesivir or any component of the formulation. Patients with ALT ≥5 times the ULN (upper limit of normal) at baseline. Renal impairment. (eGFR <30)
Monitoring	 Serum Creatinine, Biochemical profile Liver Function tests: ALT, AST, ALP, Bilirubin
Adverse Reactions	 Increased serum glucose Fever Infusion reactions



Dexamethasone Treatment Protocol



Category	Details
Dose	<u>Adult dose:</u> 6mg IV OD for 5 -10 days
Monitoring	 Serum K, Glucose, sugars Blood pressure, hemoglobin Occult blood loss WBC and Neutrophil count
Adverse effects	 Hypertension Hyperglycemia Gastric perforation
Precautions:	Cardiovascular disease: Use with caution in patients with heart failure and/or hypertension/ following acute myocardial infarction Diabetes: More frequent monitoring and dose titration of Anti-diabetic medications Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk. Myasthenia gravis: exacerbation of symptoms has occurred especially during initial treatment with corticosteroids. Seizure disorders: Seizures have been reported with adrenal crisis.
Contraindication	Hypersensitivity to dexamethasone or any component of the product Systemic fungal infection Concomitant use of more than a single dose of dexamethason with rilpivirine



Tocilizumab




- Tocilizumab can be given in COVID19 in the presence of severe cytokine storm
- Criteria of Severe Cytokine Syndrome:
 - 1. Abnormal chest imaging consistent with COVID19
 - 2. AND Laboratory parameters supportive of cytokine storm including:
 - Serum IL-6 at least 3 X ULN; OR
 - Ferritin >300 ug/L (or surrogate) with doubling within 24 hours; OR
 - Ferritin > 600 ug/L at presentation with LDH >250 U/L; OR
 - Elevated D-dimer (> 1 mg/L).
 - CRP >100 or >50 but doubled in past 48 hours
 - 3. AND Rapidly worsening gas exchange requiring >6 L/min O2, O2 sats <93% PaO2/FiO2
- Avoid use
 - Avoid use in patients with platelets <50,000 and those with ANC <1,000
 - Known hypersensitivity to tocilizumab or any component of the formulation
 - Active infections, interrupt the treatment in case of developing severe infection.
 - Patient with decompensated cirrhosis
 - Avoid in AST/ALT >1.5x upper limit of normal





- USA NIH COVID19 Guidelines: <u>https://covid19treatmentguidelines.nih.gov</u>
- Handbook of COVID-19 Prevention and Treatment , China: <u>https://covid-19.alibabacloud.com</u>
- Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, Kubin C, Barr RG, Sobieszczyk ME.
 Observational study of hydroxychloroquine in hospitalized patients with COVID-19. New England Journal of Medicine. 2020 May 7.
- Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D. Remdesivir for the Treatment of Covid-19—Preliminary Report. New England Journal of Medicine. 2020 May 22.
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine. 2020 Mar 18.
- Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020 May 11.
- Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. 2020 May 8.
- Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020 May 22.
- Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win todays battle against COVID-19?. Medical Hypotheses. 2020 May 6:109815.
- https://www.ijhsr.org/IJHSR_Vol.10_Issue.5_May2020/25.pdf



الحملة الوطنية لمكافحة فيروس كورونا (COVID-19)

COVID-19 Medication Order Sheet







Indicate choice by checking the box:

□ **Pregnancy test** for Hydroxychloroquine, Lopinavir/ritonavir, Ribavirin, or Favipiravir

□ ECG monitoring 12-lead or telemetry: (check all that apply per guideline): □ Baseline. □ 2 hours after Hydroxychloroquine dose. □ Daily. □ Every 48 hours

□ **Baseline tests**: CBC with differential, Blood Group and Vitamin D level, urea, creatinine, electrolytes serum glucose level, LFT, CRP, PCT, ESR, D-dimer, PT&PTT, Fibrinogen (repeat 24 - 48 hrs as indicated)

□ Tests to assess complicated infection: serum ferritin, LDH, triglycerides, serum lactate, Troponin-I, BNP, CK-MP, VWF and IL-6 (repeat 24 - 48 hours as indicated)

Medication	Medication Dose Contraindicat		Monitoring				
Vitamins							
□ Zinc	□ 50 mg daily	Hypersensitivity	 Serum copper serum zinc Alkaline phosphatase Mental depression taste acuity 				
U Vitamin C	🗆 1g daily	Non specific	 Renal function Hb and CBC (in patients with G6PD) 				
🗆 Vitamin D	50,000 unit's PO/NGT weekly or 2000 PO/NGT Daily	No specific contraindications	Vitamin D level				
		Antipyretics					
Paracetamol	□ 325 - 650 mg q4-6 hr Or 1 g q 6hr Not Exceed 4 g/day	Hypersensitivity Severe hepatic impairment	Relief of fever				





Medication Order sheet for Adult COVID-19

Medication		Dose	Contraindication	Monitoring		
Antivirals						
 Favipiravir Day 1: 1800mg PO/NGT BD Day 2 - 14: 800mg PO/NGT bd for (7-14 days) 		Note: Avoid in pregnancy No dose adjustment for any renal impairment. For liver impairment adjust according to the child Pugh score C: Day 1: 800 mg PO/NGT bd Day 2 - 10: 400 mg PO/NGT bd				
Hydroxychloroquine		100mg twice PO/NGT twice PO/NGT for 5 to 10 days	 G6PD Deficency QTc > 500msec , or 550msec with pacing Bundle Branch Block Epilepsy Porphyria Pre-existing Retinopathy 	 QT Interval : ECG 2-3 hours after the second dose of hydroxychloroquine, and daily thereafter. Serum Creatinine, Potassium Magnesium Liver Function tests: ALT, AST Hemoglobin level Plateletes Blood sugar 		
Remdesivir	temdesivir □□ 200 mg iv day 1 then 100 mg daily for 9 days		Hypersensitivity	 Baseline and daily (ALT, AST, Bilirubin, ALP) serum creatinine and CrCl 		
		An	ticoagulants			
Enoxaparin		once daily nigher dose if D Dimer >1000 ng/ml	HypersensitivityActive major bleeding	Bleeding parameterSerum creatinine		
- Heparin	□ 5000	Uq 8-12 hr	 Hypersensitivity Active major bleeding HIT in the past 100 days 	 Bleeding parameter 		
Fondaparinux	□ 2.5mg	SC Daily	HypersensitivityActive major bleeding	 Bleeding parameter 		





Medication		Dose	Contraindication	Monitoring			
Steroids							
 Dexamethasone (For patients who require non- invasive or invasive ventilation): 	Adult dosing: 6 mg once daily oral (liquid or tablet or IV for 5-10 days		 In pregnant or breastfeeding women, prednisolone or IV Hydrocortisone 80 mg twice daily should be us instead of Dexamethasone Take precautions when used with: Cardiovascular, diabetes, Gastrointestinal, Myasthenia graves and seizure patients 				
Methylprednisolone	1 mg/kg/day (based on actual body weight divided in 2 doses) mg □ IV or □ PO/NGT BID for 3 days		■ (If severe hypoxia persists with continued supplemental oxygen requirement on day 3, extend to a total duration of 5 - 7 days)				
Statin							
Atorvastatin	□ 40 mg PO daily		If patient receiving Lopinavir/Ritonavir, then Atorvastatin 20 mg PO daily				
🗆 Rosuvastatin	□ 20 mg PO daily		If patient receiving Lopinavir/Ritonavir, then Rosuvastatin 10 mg PO daily				
Disease modifying interleukin 6 receptor antagonist							
🗆 Tocilizumab	 □ 4-8 mg/kg/dose. Maximum 2 doses □ 50-59 kg: 400 mg IV X 1 dose □ 60-85 kg: 600 mg IV X 1 dose □ >85 kg: 800 mg IV X 1 dose 		 Laboratory criteria for patient at high risk of developing cytokine storm: Ferritin >500 mcg/l Elevated D-Dimer > 1 mg CRP>100 mg/dl LDH >250 U/L Lymphocyte count <0.8 Discontinue Interferon beta-1b 24 hours prior to dose 				



Medication Order sheet for Adult COVID-19



Medication	Dose	Contraindication	Monitoring				
Antibiotics ONLY for Community or Hospital Acquired Pneumonia :							
Vancomycin	15 mg/kgmg IV everyhours Vancomycin trough 30-minute pre 4th dose or 24 hours if re (target trough 15 - 20 mg/dl)						
Azithromycin	500 mg IV or PO Daily						
Ceftriaxone	1 or 2g IV Daily						
🗆 Cefepime	2 g IV q 8 hours:						
Piperacillin/tazobactam	g IV qhours						
🗆 Meropenem	mg IV qhours						
Doxycycline	100 mg 🗆 IV or OPO ql2 hours						

